The role of immune subtyping in glioma mRNA vaccine development
- PMID: 37431617
- DOI: 10.2217/imt-2023-0027
The role of immune subtyping in glioma mRNA vaccine development
Abstract
Studies on the development of mRNA vaccines for central nervous system tumors have used gene expression profiles, clinical data and RNA sequencing from sources such as The Cancer Genome Atlas and Chinese Glioma Genome Atlas to identify effective antigens. These studies revealed several immune subtypes of glioma, each one linked to unique prognoses and genetic/immune-modulatory changes. Potential antigens include ARPC1B, BRCA2, COL6A1, ITGB3, IDH1, LILRB2, TP53 and KDR, among others. Patients with immune-active and immune-suppressive phenotypes were found to respond better to mRNA vaccines. While these findings indicate the potential of mRNA vaccines in cancer therapy, further research is required to optimize administration and adjuvant selection, and precisely identify target antigens.
Keywords: brain tumor; central nervous system; immunotherapeutic; mRNA vaccines; mRNA-based drugs; tumors.
Plain language summary
Scientists study special vaccines for hard-to-treat brain tumors. They looked at things, such as information about patients and the small parts of cells that make up the tumor, to find ways to help. They found that brain tumors can make our body's defenses act differently. They also found some possible targets and unique defense patterns that are special to each patient when fighting these tumors. Patients with these special defenses and good targets might respond better to treatment with vaccines. This is exciting because it means that in the future, we might have treatments made for each person. But we still need to do more research to figure out how to get these vaccines to the tumor, so this research gives us hope that we can find better treatments and more choices for people with brain cancer. If we keep researching, we might find even better treatments in the future.
Similar articles
-
Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.Front Immunol. 2021 Sep 17;12:738435. doi: 10.3389/fimmu.2021.738435. eCollection 2021. Front Immunol. 2021. PMID: 34603319 Free PMC article.
-
Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.Front Immunol. 2021 Aug 27;12:709986. doi: 10.3389/fimmu.2021.709986. eCollection 2021. Front Immunol. 2021. PMID: 34512630 Free PMC article.
-
Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.Front Immunol. 2022 Feb 2;13:773264. doi: 10.3389/fimmu.2022.773264. eCollection 2022. Front Immunol. 2022. PMID: 35185876 Free PMC article.
-
Dendritic cell vaccines and immunity in glioma patients.Front Biosci. 2005 Sep 1;10:2861-81. doi: 10.2741/1743. Front Biosci. 2005. PMID: 15970541 Review.
-
Cancer vaccines: an update with special focus on ganglioside antigens.Oncol Rep. 2002 Mar-Apr;9(2):267-76. Oncol Rep. 2002. PMID: 11836591 Review.
Cited by
-
The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials.Front Oncol. 2024 Sep 27;14:1454370. doi: 10.3389/fonc.2024.1454370. eCollection 2024. Front Oncol. 2024. PMID: 39399167 Free PMC article. Review.
-
Breaking Barriers: A Future Perspective on Glioblastoma Therapy with mRNA-Based Immunotherapies and Oncolytic Viruses.Vaccines (Basel). 2024 Jan 8;12(1):61. doi: 10.3390/vaccines12010061. Vaccines (Basel). 2024. PMID: 38250874 Free PMC article.
-
Effectiveness and Safety of mRNA Vaccines in the Therapy of Glioblastoma.J Pers Med. 2024 Sep 19;14(9):993. doi: 10.3390/jpm14090993. J Pers Med. 2024. PMID: 39338247 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous